A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: paclitaxel|DRUG: Reparixin|DRUG: placebo
Sponsor: Dompé Farmaceutici S.p.A
Collaborators: PRA Health Sciences